📅 2026 Update: Advancements in Mesothelioma Treatment

Since the original article was published, there have been significant advancements in treatments for mesothelioma, particularly regarding new drug approvals. These changes reflect ongoing efforts to improve survival rates and treatment options for patients. The earlier article continues further down the page, providing foundational information on mesothelioma and related legal topics.

🧪 FDA Drug Approvals for Mesothelioma Treatments

In September 2024, the FDA approved Keytruda® (pembrolizumab) as a first-line treatment when given with pemetrexed and platinum chemotherapy for unresectable advanced or metastatic pleural mesothelioma. The KEYNOTE-483 clinical trial showed a median overall survival of 17.3 months with this combination, compared to 16.1 months for those on chemotherapy alone.

💊 New Combination Therapy Approved

The FDA also approved the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) in 2024. This combination is a first-line treatment for inoperable malignant pleural mesothelioma. The CheckMate 743 trial reported a median overall survival of 18.1 months, significantly better than the 14.1 months seen with chemotherapy alone.

🏥 Updated Surgical Guidelines

The National Comprehensive Cancer Network (NCCN) updated its guidelines in 2026, recommending pleurectomy/decortication (P/D) over extrapleural pneumonectomy (EPP) for pleural mesothelioma. The guidelines now reserve EPP for rare cases and do not recommend surgery for stages 2 through 4.

💰 Cost of New Treatments

As of October 2026, the average wholesale price for Keytruda® is approximately $10,000 per 100 mg vial. Opdivo® costs around $7,000 per 100 mg vial, and Yervoy® is about $1,200 per 50 mg vial. Treatment costs can vary based on individual needs and insurance coverage.

📌 Key Takeaways

  • 🧪 Keytruda® approved for pleural mesothelioma.
  • 💊 Opdivo® and Yervoy® combination shows improved survival.
  • 🏥 NCCN recommends P/D over EPP for surgery.
  • 💰 Keytruda® costs about $10,000 per vial.
  • 💰 Opdivo® and Yervoy® prices are approximately $7,000 and $1,200, respectively.

💡 Tips for Understanding Mesothelioma Treatment Options

Review treatment options and eligibility with your attorney to ensure you understand your specific situation.

📝 Understand New Treatments

Stay informed about the latest FDA approvals, like Keytruda® and the Opdivo® and Yervoy® combination. These treatments have shown promising results in clinical trials, offering new hope for patients.

👩‍⚕️ Consult with Your Oncologist

Discuss individual eligibility for new treatment options with your oncologist. They can help you understand which therapies might be suitable based on your specific health status and mesothelioma stage.

🏥 Consider Clinical Trials

Investigate ongoing clinical trials for mesothelioma treatments. Participation in clinical trials may provide access to cutting-edge therapies not yet widely available.

📅 Follow Up on Treatment Plans

Adhere to your treatment schedule and follow-up appointments. Consistent care is vital for monitoring your response to treatment and making adjustments as needed.

📚 Utilize Support Resources

Reach out to organizations like the Mesothelioma Applied Research Foundation and National Cancer Institute. These groups offer valuable resources and support for patients and families navigating treatment options.

🏆 Free Options Ranked by User Reviews (2026)

No national paid service currently meets the review threshold for mesothelioma resources. Instead, this section highlights free government and nonprofit organizations available for support.

🥇 1. Mesothelioma Applied Research Foundation

This nonprofit organization provides resources, support, and information on mesothelioma treatments. They help patients understand available treatment options and connect them with clinical trials.

🥈 2. National Cancer Institute (NCI)

The NCI offers comprehensive information on mesothelioma, including treatment options and clinical trials. Their website serves as a valuable resource for patients seeking assistance and understanding their condition.

🔎 Important Considerations

  • 🔍 Always verify the credentials of any organization offering help.
  • 📄 Check for reviews or testimonials from other patients.
  • 🎯 Ensure the organization provides relevant information for your specific situation.
  • 📞 Contact support representatives to ask questions and clarify doubts.

❓ Frequently Asked Questions

❔ What are the main types of treatment for mesothelioma?

Treatment options for mesothelioma include chemotherapy, surgery, and radiation therapy. New immunotherapies are also being explored to improve outcomes.

🏥 How do I know if I am eligible for new treatments?

Eligibility for new treatments like Keytruda® or the Opdivo® and Yervoy® combination is assessed by your oncologist based on your health status and cancer stage.

📅 What should I expect during clinical trials?

Clinical trials often involve a detailed screening process. Participants may experience different treatment protocols and receive close monitoring by medical professionals.

🧪 Are there risks associated with new treatments?

As with any medical treatment, new therapies can have side effects. Discuss potential risks and benefits with your healthcare provider before starting any new treatment.

💰 How can I manage the costs of mesothelioma treatment?

Understanding your insurance coverage and exploring financial assistance options from nonprofit organizations can help manage treatment costs.

📚 Where can I find support for mesothelioma?

Patients can find support through organizations like the Mesothelioma Applied Research Foundation and the National Cancer Institute, which provide valuable resources and information.

⚖️ Recent Cases Related to Mesothelioma Treatment

Recent court rulings reflect ongoing legal matters concerning mesothelioma treatment and patient rights. These rulings can impact how treatments are accessed and the responsibilities of healthcare providers.

For more detailed information, you can browse more rulings on the news page.

End of October 2026 Update






 



Mesothelioma Drugs



What is Carboplatin?

Carboplatin


Carboplatin is a chemotherapy drug administered to patients to fight some forms of cancer, including lung, head, neck and mesothelioma cancers. Carboplatin was introduced during the late 1980s and has since become popular during the clinical treatment of the aforementioned diseases. 



Carboplatin’s popularity stems from the fact that the drug imposes few side effects, especially when compared to its parent compound cisplatin. 



Carboplatin, which is commonly referred to by its brand name Paraplatin, was formally approved by the Food and Drug Administration in 1989. Carboplatin is a modified form of Cisplatin, which was commonly used to fight mesothelioma and other forms of lung cancer during the 1970s. 



Chemotherapy drugs, such as carboplatin, work in a variety of ways. Carboplatin’s efficacy is found in its ability to break through the cell walls and adhere to the cell’s DNA. This attaching property impedes the cell from dividing (cancer cells divide very rapidly). Drugs like carboplatin are attracted to these cells are therefore able to target specific cancer cells. In this light, carboplatin serves as an alkylating agent which means it is able to attach to the cancer cell’s DNA, ultimately leading to the cell’s death. 



Side Effects of Carboplatin:



In comparison to cisplatin, the most tangible benefit offered by carboplatin is found in its ability to reduce side effects, particularly the elimination of nephrotoxic properties. Vomiting and nausea are easily controlled and far less severe in carboplatin when compared to other chemotherapy drugs. 



The primary drawback associated with carboplatin use stems from its myelosuppressive effect. This side effect causes platelet and blood cell production of bone morrow in the body to rapidly decrease, sometimes to as low as 105 of its natural production levels. 



Carboplatin is not as strong as cisplatin; depending on the patient’s cancer, carboplating may have 1/8th to 1/45th the effectiveness of its sister drug. The clinical standard of dosage for the drug is typically a 4:1 ratio compared to cisplatin—four times the amount of carboplatin is needed to achieve the same efficacy as one dose of cisplatin. 



How does Carboplatin Fight Mesothelioma Cancer?



Carboplatin is used to combat several different forms of cancer, but is most commonly administered to treat lung cancer. Carboplatin is typically conducted as a day patient treatment method, involving a blood culture the day before. Carboplatin is administered via infusion; the regimen is administered as a 21-day cycle. On the first day of mesothelioma treatment, the patient is administered both gemcitabine and carboplating. The following week, on the same day, the mesothelioma patient is only given a small dose of gemcitabine. There then follows a recuperation period of approximately two weeks, which compeltes the carboplatin cycle for mesothelioma cancer. 



The following cycle is administered after the rest period concludes and ends three weeks after the first injection of carboplatin. Typically 4-6 cycles of mesothelioma treatment are provided over a period of 3-4 months to complete the full course of treatment. This form of mesothelioma treatment aims at preventing the further proliferation of the cancer or in some cases a reduction of the mesothelioma tumor by as much as 80%. 



Medical professionals are constantly searching for effective ways to treat mesothelioma cancer. A number of clinical trials are currently underway to test various chemotherapy drugs, which are often combined with one another to determine an appropriate mix to battle disease. Clinical trials are frequently conducted to find the most effective means to fight malignant mesothelioma. Carboplatin is often used in these trials and in combination with other mesothelioma drugs to find a more effective treatment method. 



Phase I Clinical Trials combining Carboplatin and other mesothelioma drugs will determine what combinations are effective in fighting the cancer. When researchers pinpoint a combination that appears effective, Phase II Clinical trials commence. Results of said trials reveal that carboplatin in combination with pemetrexed may prove effecting in fighting mesothelioma cancer. Moreover, several studies have shown that carboplatin, when combined with Alimta, is moderately effective, with minimal toxicity, in fighting mesothelioma cancer. 



There are several on-going clinical trials that utilize carboplatin in combination with other chemotherapy drugs to treat mesothelioma cancer. These trials are currently recruiting mesothelioma patients to observe efficacy rates.